Abstract
In its second cardiovascular disease-focused purchase of 2013, AstraZeneca has agreed to acquire Omthera Pharmaceuticals for approximately US$323 M plus Contingent Value Rights that equate to approximately US$120 M in total. With the acquisition, AstraZeneca will gain Omthera’s sole product candidate Epanova™, an omega-3 free fatty acid composition that has successfully completed two Phase III trials in patients with hypertriglyceridaemia and which will face competition in the prescription omega-3 market from GlaxoSmithKline’s Lovaza® (omega-3-acid ethyl esters) and Amarin’s Vascepa® (icosapent ethyl).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
